Fennec Pharmaceuticals (FENC) Cost of Revenue (2023 - 2026)

Fennec Pharmaceuticals (FENC) has 3 years of Cost of Revenue data on file, last reported at $1.8 million in Q4 2025.

• Quarterly Cost of Revenue rose 163.68% year-over-year to $1.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.8 million (up 18.22% YoY) and the FY2025 annual result came in at $3.8 million, up 18.22% from the prior year.
• Cost of Revenue rose to $1.8 million in Q4 2025, from $660000.0 in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $1.8 million in Q4 2025 to a low of $95000.0 in Q1 2023.
• A 3-year average of $683916.7 and a median of $634000.0 in 2024 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2024 — Cost of Revenue surged 478.95% — and 2025, when it slumped 51.36%.
• Tracing FENC's Cost of Revenue over 3 years: stood at $685000.0 in 2023, then fell by 2.34% to $669000.0 in 2024, then surged by 163.68% to $1.8 million in 2025.
• The last three Cost of Revenue figures came in at $1.8 million (Q4 2025), $660000.0 (Q3 2025), and $967000.0 (Q2 2025), per Business Quant data.